EUK 189

Drug Profile

EUK 189

Alternative Names: EUK-189; Synthetic catalytic scavenger

Latest Information Update: 09 Jan 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Proteome Systems
  • Developer Tyrian Diagnostics
  • Class Organometallic compounds; Salicylates; Small molecules
  • Mechanism of Action Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cognition disorders; Radiation-induced skin damage

Most Recent Events

  • 09 Jan 2009 Discontinued - Phase-I for Radiation-induced skin damage in USA (Topical)
  • 10 May 2007 Minerva Healthcare Inc. granted an option to license EUK 189 and other topical Eukarion compounds
  • 17 Nov 2006 Phase-I clinical trials in Radiation-induced skin damage in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top